LF 20-0383

Drug Profile

LF 20-0383

Alternative Names: LF 216

Latest Information Update: 05 Oct 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fournier Pharma
  • Class
  • Mechanism of Action Interleukin 8 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Chronic obstructive pulmonary disease; Rheumatoid arthritis

Most Recent Events

  • 07 Jan 2004 No development reported - Preclinical for Adult respiratory distress syndrome in France (unspecified route)
  • 07 Jan 2004 No development reported - Preclinical for Chronic obstructive pulmonary disease in France (unspecified route)
  • 07 Jan 2004 No development reported - Preclinical for Rheumatoid arthritis in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top